^
    4ms
    A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) (clinicaltrials.gov)
    P1/2, N=130, Recruiting, AbbVie | Not yet recruiting --> Recruiting
    Enrollment open • Adverse events
    |
    Darzalex (daratumumab) • dexamethasone • pomalidomide • surzetoclax (ABBV-453)
    6ms
    A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (clinicaltrials.gov)
    P1, N=4, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting | N=80 --> 4
    Enrollment closed • Enrollment change • Adverse events
    |
    Gazyva (obinutuzumab) • surzetoclax (ABBV-453)
    7ms
    A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) (clinicaltrials.gov)
    P1/2, N=130, Not yet recruiting, AbbVie
    New P1/2 trial • Adverse events
    |
    Darzalex (daratumumab) • dexamethasone • pomalidomide • surzetoclax (ABBV-453)
    10ms
    A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (clinicaltrials.gov)
    P1, N=80, Recruiting, AbbVie | Initiation date: Aug 2024 --> Jan 2025
    Trial initiation date • Adverse events
    |
    Gazyva (obinutuzumab) • surzetoclax (ABBV-453)
    1year
    A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets (clinicaltrials.gov)
    P1, N=34, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting | N=360 --> 34 | Trial completion date: Aug 2026 --> Dec 2025 | Trial primary completion date: Aug 2026 --> Feb 2024
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Adverse events • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Chr t(11;14)
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone • surzetoclax (ABBV-453)
    over1year
    A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (clinicaltrials.gov)
    P1, N=80, Recruiting, AbbVie | Not yet recruiting --> Recruiting
    Enrollment open • Adverse events
    |
    Gazyva (obinutuzumab) • surzetoclax (ABBV-453)
    almost2years
    A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (clinicaltrials.gov)
    P1, N=80, Not yet recruiting, AbbVie
    New P1 trial • Adverse events
    |
    Gazyva (obinutuzumab) • surzetoclax (ABBV-453)
    almost2years
    A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets (clinicaltrials.gov)
    P1, N=360, Recruiting, AbbVie | Trial completion date: Apr 2026 --> Aug 2026 | Trial primary completion date: Apr 2026 --> Aug 2026
    Trial completion date • Trial primary completion date • Adverse events • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Chr t(11;14)
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone • surzetoclax (ABBV-453)
    2years
    A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets (clinicaltrials.gov)
    P1, N=360, Recruiting, AbbVie | N=48 --> 360
    Enrollment change • Adverse events • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Chr t(11;14)
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone • surzetoclax (ABBV-453)
    over2years
    A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets (clinicaltrials.gov)
    P1, N=48, Recruiting, AbbVie | N=21 --> 48
    Enrollment change • Adverse events • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Chr t(11;14)
    |
    lenalidomide • Darzalex (daratumumab) • surzetoclax (ABBV-453)
    almost3years
    A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets (clinicaltrials.gov)
    P1, N=21, Recruiting, AbbVie | Trial primary completion date: Aug 2025 --> Apr 2026
    Trial primary completion date • Adverse events • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Chr t(11;14)
    |
    surzetoclax (ABBV-453)
    over3years
    A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets (clinicaltrials.gov)
    P1, N=21, Recruiting, AbbVie | Not yet recruiting --> Recruiting
    Enrollment open • Adverse events • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    surzetoclax (ABBV-453)